Breakingviews on Twitter
Search League Tables

Tuesday, 31 May 2016

Evonik finally gets its IPO chemistry right

Fourth time lucky

The German specialty chemicals group has aborted IPO plans three times since 2008. As it prepares to try again, investors should think afresh. Evonik is handsomely profitable and well positioned for growth. It looks like an attractive investment.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.

Sign In

(Launches in a new window)